Developer docs
API playgroundTry for free, no card

Search company profiles

CSA Medical

Full company profile

uuid0000sa6

Namestring
CSA Medical
Legal namestring
CSA Medical, Inc.
Websiteurl
rejuvenair.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

CSA Medical is a privately held US medical device company developing the RejuvenAir System, a bronchoscopic spray cryotherapy platform designed to treat the underlying cause of chronic bronchitis in patients with COPD. The company's core technology, Metered CryoSpray (MCS), delivers precise doses of -196°C liquid nitrogen through a unique circumferential cryospray catheter and proprietary energy control algorithm that flash-freezes damaged airway cells while preserving the extracellular matrix, enabling a rejuvenative healing response with regrowth of healthy cilia and mucus-producing cells. CSA Medical has been granted FDA Breakthrough Device Designation and, in January 2026, submitted a Premarket Approval (PMA) application to the FDA supported by positive results from the SPRAY-CB pivotal trial across 20+ US clinical sites, with over 500 procedures completed and zero pneumothoraces reported. The RejuvenAir System received CE Mark approval in the EU in December 2019 and is commercially available in Europe.

The company targets the more than 9 million Americans and 23 million Europeans diagnosed with chronic bronchitis, a large COPD subset underserved by current symptom-management pharmacotherapy. CSA Medical's go-to-market motion centers on interventional pulmonologists at major academic and tertiary medical centers, with the SPRAY-CB clinical trial network (Temple, Cleveland Clinic, Duke, Beth Israel Deaconess, UC Davis, UT Southwestern, etc.) forming the foundation for its post-approval US enterprise sales channel. Revenue model is hardware-based device and consumable sales to hospitals; the device is investigational in the US (pre-revenue) and commercially sold in the EU. The company has raised over $150 million across multiple venture rounds, including a $53 million Series D in September 2024 led by TVM Capital Life Science and Yonjin Ventures. CSA Medical is led by President and CEO Wendelin Maners, with Heather Nigro serving as SVP of Regulatory, Quality and Clinical Affairs.

Short descriptiontext

CSA Medical is a US private medical device company developing the RejuvenAir System, a bronchoscopic liquid nitrogen spray cryotherapy platform that targets the underlying cause of chronic bronchitis in COPD patients. It serves interventional pulmonologists and major medical centers, holds FDA Breakthrough Designation, has submitted a PMA in January 2026, and is CE Mark commercial in the EU.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spray cryotherapy devices, chronic bronchitis treatment, interventional pulmonology devices, COPD respiratory therapy, cryosurgical medical devices
Industry2 codes
PRIMARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Respiratory Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales - RejuvenAir System
TypeHardware Sales
Description

CSA Medical is a medical device company developing the RejuvenAir System for treating chronic bronchitis. The company is currently pre-revenue in the US as the device is investigational. The device received CE Mark approval in the EU in December 2019 and is commercially available there. Upon FDA PMA approval, the company plans to commercialize in the US through interventional pulmonologists at hospitals and medical centers.

rejuvenair.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RejuvenAir
Description

RejuvenAir System - A breakthrough medical device using Metered CryoSpray therapy for the treatment of chronic bronchitis in COPD patients. The system applies precise thermal dose of extremely cold (-196°C) liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure.

rejuvenair.com
Core offering1 text field

CSA Medical develops and manufactures the RejuvenAir System, a cryosurgical medical device that applies metered doses of -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure to treat chronic bronchitis in COPD patients. The Metered CryoSpray (MCS) technology destroys damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cilia and mucus-producing cells. The system is approved in the EU (CE Mark, December 2019) and under FDA Premarket Approval review in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SPRAY-CB pivotal trial met primary endpoint and multiple secondary endpoints with statistical significance
+4 more records
Product overview1 text field

CSA Medical is a medical device company with a single unified product offering: the RejuvenAir System. This system utilizes Metered CryoSpray (MCS) technology to deliver liquid nitrogen cryotherapy bronchoscopically to treat the underlying cause of chronic bronchitis in COPD patients. The RejuvenAir System is designed to destroy damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cells including cilia and normal mucus-producing cells.

Product and service1 record
1RejuvenAir System
CategoryRespiratory Medical Device — Spray Cryotherapy System
Description

A cryosurgical medical device that delivers metered doses of -196°C liquid nitrogen spray (Metered CryoSpray technology) to targeted areas within the lungs through a minimally invasive, outpatient bronchoscopic procedure. The system ablates damaged airway cells while preserving the extracellular matrix, enabling rejuvenative healing in COPD patients with chronic bronchitis. Sold to interventional pulmonology departments at hospitals and academic medical centers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Researchers at NHLI, Imperial College London conducted mechanism of action studies demonstrating rejuvenative healing after MCS treatment. Found reduction in abnormal lung epithelium morphology and altered DNA methylation pathways linking tissue regeneration to quality of life improvements. Presented findings at ERS Congress.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Christopher Orton and Professor Pallav Shah conducted pivotal European feasibility studies and first randomized controlled study. Presented 36-month data showing safety and efficacy. Principal investigators for mechanism of action studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial site. Dr. Gerard J. Criner, Chair and Professor of Thoracic Medicine and Surgery, performed the first SPRAY-CB procedure on October 14, 2020.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology / Pulmonary Care.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology / Pulmonary Care.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Adnan Majid, Interventional Pulmonology / Pulmonary Care.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Wahidi, Interventional Pulmonology / Pulmonary Care.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Gildea, Interventional Pulmonology / Pulmonary Care.

9Walter Reed National Military Medical Center
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Dr. Robert Browning Jr., Professor of Medicine and Medical Director of Interventional Pulmonology, has presented RejuvenAir technology development and clinical data at medical conferences.

rejuvenair.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pulmonx markets the Zephyr Endobronchial Valve System, a bronchoscopic device for treating severe emphysema/COPD. It is the most directly comparable commercial-stage interventional pulmonology company, addressing the same patient population with a different bronchoscopic lung volume reduction mechanism.

TypeEmerging player
Description

Nuvaira is developing targeted lung denervation (TLD) for COPD, a catheter-based bronchoscopic procedure targeting airway neural hyperactivity. It is an emerging interventional pulmonology player addressing the same COPD population with a different mechanism and represents a future competitor to RejuvenAir.

TypeBroad incumbent
Description

Spiration, acquired by Olympus, developed the Spiration Valve System for emphysema and is part of Olympus's broader interventional pulmonology portfolio. Comparable as a bronchoscopic lung volume reduction modality, but Olympus offers a much wider respiratory/endoscopy product portfolio.

TypeBroad incumbent
Description

Medtronic has a significant interventional pulmonology and lung cancer diagnostics franchise, including acquired technologies in bronchoscopy navigation and ablation. Comparable as a broad incumbent with overlapping capabilities in interventional pulmonology, though it does not focus specifically on chronic bronchitis spray cryotherapy.

TypeBroad incumbent
Description

Boston Scientific acquired BTG/PneumRx (coils for emphysema) and has a broader interventional pulmonary portfolio. It is comparable as a large incumbent player in interventional lung therapies, but its portfolio spans multiple specialties beyond chronic bronchitis.

TypeBroad incumbent
Description

Johnson & Johnson acquired Auris Health (Monarch robotic bronchoscopy platform), positioning itself in the interventional pulmonology space for lung cancer diagnosis and therapy. While focused on robotic bronchoscopy, it represents a large incumbent competing for interventional pulmonology procedure volume and KOL mindshare.

TypeEmerging player
Description

Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems. Comparable as an emerging player in the bronchoscopic interventional space serving interventional pulmonologists, although its primary focus is lung cancer diagnostics rather than COPD therapy.

TypeOthers
Description

Intuitive Surgical is the leader in robotic-assisted surgery including thoracic applications via the da Vinci platform. While not a direct competitor to spray cryotherapy for chronic bronchitis, it competes for interventional pulmonology procedural share and capital budgets at major medical centers.

TypeOthers
Description

Penumbra develops catheter-based technologies primarily for vascular thrombectomy, with emerging presence in respiratory and other specialties. Not a direct competitor, but a relevant catheter-based medical device peer with similar scale and growth trajectory in interventional therapies.

10Steris
TypeOthers
Description

Steris provides sterilization, infection prevention, and procedural support products used widely in endoscopy and bronchoscopy suites. Relevant as an adjacent enabling participant whose products support the broader interventional pulmonology procedural ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CSA Medical

Respiratory Medical Devicesrejuvenair.com

CSA Medical is a US private medical device company developing the RejuvenAir System, a bronchoscopic liquid nitrogen spray cryotherapy platform that targets the underlying cause of chronic bronchitis in COPD patients. It serves interventional pulmonologists and major medical centers, holds FDA Breakthrough Designation, has submitted a PMA in January 2026, and is CE Mark commercial in the EU.

What CSA Medical does

CSA Medical is a privately held US medical device company developing the RejuvenAir System, a bronchoscopic spray cryotherapy platform designed to treat the underlying cause of chronic bronchitis in patients with COPD. The company's core technology, Metered CryoSpray (MCS), delivers precise doses of -196°C liquid nitrogen through a unique circumferential cryospray catheter and proprietary energy control algorithm that flash-freezes damaged airway cells while preserving the extracellular matrix, enabling a rejuvenative healing response with regrowth of healthy cilia and mucus-producing cells. CSA Medical has been granted FDA Breakthrough Device Designation and, in January 2026, submitted a Premarket Approval (PMA) application to the FDA supported by positive results from the SPRAY-CB pivotal trial across 20+ US clinical sites, with over 500 procedures completed and zero pneumothoraces reported. The RejuvenAir System received CE Mark approval in the EU in December 2019 and is commercially available in Europe.

The company targets the more than 9 million Americans and 23 million Europeans diagnosed with chronic bronchitis, a large COPD subset underserved by current symptom-management pharmacotherapy. CSA Medical's go-to-market motion centers on interventional pulmonologists at major academic and tertiary medical centers, with the SPRAY-CB clinical trial network (Temple, Cleveland Clinic, Duke, Beth Israel Deaconess, UC Davis, UT Southwestern, etc.) forming the foundation for its post-approval US enterprise sales channel. Revenue model is hardware-based device and consumable sales to hospitals; the device is investigational in the US (pre-revenue) and commercially sold in the EU. The company has raised over $150 million across multiple venture rounds, including a $53 million Series D in September 2024 led by TVM Capital Life Science and Yonjin Ventures. CSA Medical is led by President and CEO Wendelin Maners, with Heather Nigro serving as SVP of Regulatory, Quality and Clinical Affairs.

CSA Medical firmographics

Firmographics
Name
CSA Medical
Legal name
CSA Medical, Inc.
Website
https://rejuvenair.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
CSA Medical is a US private medical device company developing the RejuvenAir System, a bronchoscopic liquid nitrogen spray cryotherapy platform that targets the underlying cause of chronic bronchitis in COPD patients. It serves interventional pulmonologists and major medical centers, holds FDA Breakthrough Designation, has submitted a PMA in January 2026, and is CE Mark commercial in the EU.
Ownership category
akta.pro rank

CSA Medical industry classification

Industry
Product category
Respiratory Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKANAJ
Bronchoscopy & Interventional Pulmonology
SECONDARYHLAKANAE
COPD & Chronic Bronchitis Management

Keywords

  • Spray cryotherapy devices
  • Chronic bronchitis treatment
  • Interventional pulmonology devices
  • COPD respiratory therapy
  • Cryosurgical medical devices

Where CSA Medical is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CSA Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales - RejuvenAir System: CSA Medical is a medical device company developing the RejuvenAir System for treating chronic bronchitis. The company is currently pre-revenue in the US as the device is investigational. The device received CE Mark approval in the EU in December 2019 and is commercially available there. Upon FDA PMA approval, the company plans to commercialize in the US through interventional pulmonologists at hospitals and medical centers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

CSA Medical product offering

Product offering

Core offering

CSA Medical develops and manufactures the RejuvenAir System, a cryosurgical medical device that applies metered doses of -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure to treat chronic bronchitis in COPD patients. The Metered CryoSpray (MCS) technology destroys damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cilia and mucus-producing cells. The system is approved in the EU (CE Mark, December 2019) and under FDA Premarket Approval review in the United States.

Product overview

CSA Medical is a medical device company with a single unified product offering: the RejuvenAir System. This system utilizes Metered CryoSpray (MCS) technology to deliver liquid nitrogen cryotherapy bronchoscopically to treat the underlying cause of chronic bronchitis in COPD patients. The RejuvenAir System is designed to destroy damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cells including cilia and normal mucus-producing cells.

Differentiator

Problem solved

Functional benefit

Brands

  • RejuvenAir: RejuvenAir System - A breakthrough medical device using Metered CryoSpray therapy for the treatment of chronic bronchitis in COPD patients. The system applies precise thermal dose of extremely cold (-196°C) liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure.

Products and services

  • RejuvenAir System A cryosurgical medical device that delivers metered doses of -196°C liquid nitrogen spray (Metered CryoSpray technology) to targeted areas within the lungs through a minimally invasive, outpatient bronchoscopic procedure. The system ablates damaged airway cells while preserving the extracellular matrix, enabling rejuvenative healing in COPD patients with chronic bronchitis. Sold to interventional pulmonology departments at hospitals and academic medical centers.

Quantifiable outcome

  • SPRAY-CB pivotal trial met primary endpoint and multiple secondary endpoints with statistical significance
  • +4 more outcomes

Companies that use CSA Medical

Customer profile

Named customers9 records

Segments1 record

Ideal customer profiles1 record

CSA Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CSA Medical partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and major.

  • Imperial College London (National Heart and Lung Institute)coreStrategic or Co-development PartnerResearchers at NHLI, Imperial College London conducted mechanism of action studies demonstrating rejuvenative healing after MCS treatment. Found reduction in abnormal lung epithelium morphology and altered DNA methylation pathways linking tissue regeneration to quality of life improvements. Presented findings at ERS Congress.
  • Royal Brompton Hospital, LondoncoreStrategic or Co-development PartnerDr. Christopher Orton and Professor Pallav Shah conducted pivotal European feasibility studies and first randomized controlled study. Presented 36-month data showing safety and efficacy. Principal investigators for mechanism of action studies.
  • Temple University (Temple Lung Center)coreStrategic or Co-development PartnerSPRAY-CB pivotal trial site. Dr. Gerard J. Criner, Chair and Professor of Thoracic Medicine and Surgery, performed the first SPRAY-CB procedure on October 14, 2020.
  • UC Davis Medical CentermajorStrategic or Co-development PartnerSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology / Pulmonary Care.
  • UT Southwestern Medical CentermajorStrategic or Co-development PartnerSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology / Pulmonary Care.
  • Beth Israel Deaconess Medical CentermajorStrategic or Co-development PartnerSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Adnan Majid, Interventional Pulmonology / Pulmonary Care.
  • Duke University School of MedicinemajorStrategic or Co-development PartnerSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Wahidi, Interventional Pulmonology / Pulmonary Care.
  • The Cleveland Clinic FoundationmajorStrategic or Co-development PartnerSPRAY-CB pivotal trial clinical site; Principal Investigator: Dr. Gildea, Interventional Pulmonology / Pulmonary Care.
  • Walter Reed National Military Medical CentermajorStrategic or Co-development PartnerDr. Robert Browning Jr., Professor of Medicine and Medical Director of Interventional Pulmonology, has presented RejuvenAir technology development and clinical data at medical conferences.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

CSA Medical competitors and assessment

Company assessment

Direct peers

  • Pulmonx: Pulmonx markets the Zephyr Endobronchial Valve System, a bronchoscopic device for treating severe emphysema/COPD. It is the most directly comparable commercial-stage interventional pulmonology company, addressing the same patient population with a different bronchoscopic lung volume reduction mechanism.

Emerging players

  • Nuvaira: Nuvaira is developing targeted lung denervation (TLD) for COPD, a catheter-based bronchoscopic procedure targeting airway neural hyperactivity. It is an emerging interventional pulmonology player addressing the same COPD population with a different mechanism and represents a future competitor to RejuvenAir.
  • Broncus Medical: Broncus Medical develops interventional pulmonology tools including lung navigation and biopsy systems. Comparable as an emerging player in the bronchoscopic interventional space serving interventional pulmonologists, although its primary focus is lung cancer diagnostics rather than COPD therapy.

Broad incumbents

  • Spiration (Olympus): Spiration, acquired by Olympus, developed the Spiration Valve System for emphysema and is part of Olympus's broader interventional pulmonology portfolio. Comparable as a bronchoscopic lung volume reduction modality, but Olympus offers a much wider respiratory/endoscopy product portfolio.
  • Medtronic: Medtronic has a significant interventional pulmonology and lung cancer diagnostics franchise, including acquired technologies in bronchoscopy navigation and ablation. Comparable as a broad incumbent with overlapping capabilities in interventional pulmonology, though it does not focus specifically on chronic bronchitis spray cryotherapy.
  • Boston Scientific: Boston Scientific acquired BTG/PneumRx (coils for emphysema) and has a broader interventional pulmonary portfolio. It is comparable as a large incumbent player in interventional lung therapies, but its portfolio spans multiple specialties beyond chronic bronchitis.
  • Johnson & Johnson (Auris Health): Johnson & Johnson acquired Auris Health (Monarch robotic bronchoscopy platform), positioning itself in the interventional pulmonology space for lung cancer diagnosis and therapy. While focused on robotic bronchoscopy, it represents a large incumbent competing for interventional pulmonology procedure volume and KOL mindshare.

Others

  • Intuitive Surgical: Intuitive Surgical is the leader in robotic-assisted surgery including thoracic applications via the da Vinci platform. While not a direct competitor to spray cryotherapy for chronic bronchitis, it competes for interventional pulmonology procedural share and capital budgets at major medical centers.
  • Penumbra: Penumbra develops catheter-based technologies primarily for vascular thrombectomy, with emerging presence in respiratory and other specialties. Not a direct competitor, but a relevant catheter-based medical device peer with similar scale and growth trajectory in interventional therapies.
  • Steris: Steris provides sterilization, infection prevention, and procedural support products used widely in endoscopy and bronchoscopy suites. Relevant as an adjacent enabling participant whose products support the broader interventional pulmonology procedural ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CSA Medical social profiles

Digital presence

CSA Medical compliance and trust

Trust signal

Compliance2 records

CSA Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CSA Medical leadership team

Management profile

Number of profiles

Profiles3 records

CSA Medical funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CSA Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSA Medical

What does CSA Medical do?

CSA Medical develops and manufactures the RejuvenAir System, a cryosurgical medical device that applies metered doses of -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive bronchoscopic procedure to treat chronic bronchitis in COPD patients. The Metered CryoSpray (MCS) technology destroys damaged airway cells while preserving the extracellular matrix, enabling regrowth of healthy cilia and mucus-producing cells. The system is approved in the EU (CE Mark, December 2019) and under FDA Premarket Approval review in the United States.

Is CSA Medical a public or private company?

CSA Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was CSA Medical founded?

CSA Medical was founded in 2006. It employs 11 to 50 people.

Where is CSA Medical based?

CSA Medical is headquartered in Lexington, United States, in the North America region.

How does CSA Medical make money?

One revenue line is on record: medical Device Sales - RejuvenAir System.

Who are CSA Medical's main competitors?

Pulmonx is listed as a direct peer. Emerging players are Nuvaira and Broncus Medical. Broad incumbents are Spiration (Olympus), Medtronic, Boston Scientific and Johnson & Johnson (Auris Health). Others are Intuitive Surgical, Penumbra and Steris.

Does CSA Medical have an API?

No public API is recorded for CSA Medical.

What industry is CSA Medical in?

CSA Medical's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLAKANAJ, Bronchoscopy & Interventional Pulmonology, with a secondary code of HLAKANAE, COPD & Chronic Bronchitis Management. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comLeading Companies Reinforcing Their Presence in the Medical Grade Liquid Nitrogen MarketThe medical grade liquid nitrogen market is projected to grow to $3.39 billion by 2030, driven by rising demand for regenerative medicine, cell and gene therapy storage, and cryosurgical applications, with a compound annual growth rate of 6.4%. In January 2023, Linde plc fully acquired nexAir, LLC to strengthen its packaged gas distribution network and medical-grade liquid nitrogen supply chain across the United States. In July 2024, CSA Medical Inc. completed patient enrollment for its pivotal SPRAY-CB trial of the RejuvenAir System, a cryotherapy device using liquid nitrogen spray to treat chronic bronchitis.PR NewswireCSA Medical Submits PMA for RejuvenAir® System Following Positive Results from Pivotal SPRAY-CB TrialCSA Medical submitted a Premarket Approval application to the FDA for its RejuvenAir System to treat chronic bronchitis in COPD patients, supported by positive results from the SPRAY-CB pivotal clinical trial that met its primary endpoint and multiple secondary endpoints with statistical significance. The RejuvenAir System, which uses Metered CryoSpray therapy delivered bronchoscopically, received FDA Breakthrough Device Designation and has potential to become the first FDA-approved device-based treatment for chronic bronchitis. The company stated it looks forward to continuing collaborative review with the FDA toward potential U.S. commercialization.SecSEC FORM DCSA Medical, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(b). The company disclosed a total offering amount of approximately $71.2 million, which includes the conversion of over $35.4 million in principal and interest from outstanding convertible notes.FinSMEsCSA Medical Raises $53M in Series D FinancingCSA Medical raised $53M in Series D funding co-led by TVM Capital Life Science and Yonjin Venture. The Boston-based developer will use the funds to finance its US launch of its RejuvenAir cryotherapy device, targeting chronic bronchitis patients.Venture Capital Access OnlineCSA Medical Raises $53 Million in Series D Financing to Support PMA of the RejuvenAir SystemCSA Medical Inc. completed an oversubscribed $53 million Series D financing round led by TVM Capital Life Science and Yonjin Ventures to fund the premarket approval (PMA) process for its RejuvenAir System. The capital will support regulatory submissions with the U.S. Food and Drug Administration and the development of a commercialization strategy for the device, which uses liquid nitrogen spray cryotherapy to treat chronic bronchitis.Pulse 2.0CSA Medical: $53 Million (Series D) Raised For Advancing RejuvenAir SystemCSA Medical announced the completion of a $53 million Series D equity financing round led by TVM Capital Life Science and Yonjin Ventures. The funds will support the company through FDA premarket approval for its RejuvenAir System and the development of a commercialization strategy for a U.S. launch.VC News DailyCSA Medical Raises $53M in Series D FinancingCSA Medical, based in Boston, MA, has raised $53 million in an oversubscribed Series D financing round to support its RejuvenAir System for treating chronic bronchitis. The funds will be utilized to progress toward FDA premarket approval and to establish a commercialization strategy in the U.S.PR NewswireCSA Medical Announces 500th Metered CryoSpray Procedure for the Treatment of Chronic BronchitisCSA Medical announced the 500th Metered CryoSpray Procedure using its RejuvenAir System, performed by Dr. Jonathan S. Kurman at the Froedtert & Medical College of Wisconsin health network as part of the U.S. pivotal trial SPRAY-CB. The device, which applies liquid nitrogen at -196°C to ablate damaged airway cells in chronic bronchitis patients, is not yet commercially available in the United States and remains under clinical investigation for FDA approval. European trial results have shown statistically significant and clinically meaningful improvements in patient symptoms, with the U.S. trial currently enrolling across multiple centers.PR NewswireCSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic BronchitisCSA Medical announced completion of enrollment in its Mechanism of Action study for the RejuvenAir System, which investigates how Metered CryoSpray reduces mucus-producing goblet cells and promotes regrowth of healthy cilia in COPD patients with chronic bronchitis. The company is also conducting the pivotal SPRAY-CB Study across twenty sites in the United States, with the device having received CE mark approval in the EU and Breakthrough Device designation from the FDA. The research aims to provide cellular-level rationale for the airway remodeling response observed in earlier feasibility studies.PR NewswireCSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic BronchitisCSA Medical, Inc. announced that Cooper University Health Care has become the 20th clinical site to join the SPRAY-CB pivotal study for treating chronic bronchitis. The study investigates the RejuvenAir System, a device utilizing metered cryospray therapy to address mucus overproduction in COPD patients. This expansion supports ongoing clinical investigations into the device's efficacy in the United States.